Neo Ivy Capital Management Sells 276,683 Shares of ADMA Biologics Inc (NASDAQ:ADMA)

Key Points

• Neo Ivy Capital Management drastically reduced its stake in ADMA Biologics by 93%, now holding only 20,944 shares after selling 276,683 shares in the first quarter.
• ADMA Biologics reported earnings of $0.14 per share for the quarter, below analysts' expectations of $0.16, while revenue increased by 40.2% year-over-year.
• Analyst ratings have varied, with Raymond James raising the price target from $25.00 to $32.00, while Wall Street Zen downgraded the stock from "hold" to "sell."

Neo Ivy Capital Management cut its position in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 93.0% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 20,944 shares of the biotechnology company's stock after selling 276,683 shares during the quarter. Neo Ivy Capital Management's holdings in ADMA Biologics were worth $416,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. B Group Inc. purchased a new stake in ADMA Biologics during the fourth quarter valued at about $39,231,000. Raymond James Financial Inc. purchased a new stake in shares of ADMA Biologics during the fourth quarter worth about $19,076,000. Arrowstreet Capital Limited Partnership grew its stake in shares of ADMA Biologics by 57.9% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 2,762,700 shares of the biotechnology company's stock worth $47,380,000 after purchasing an additional 1,013,456 shares during the last quarter. Dimensional Fund Advisors LP raised its position in ADMA Biologics by 16.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 4,668,320 shares of the biotechnology company's stock valued at $80,065,000 after purchasing an additional 643,661 shares during the last quarter. Finally, Man Group plc raised its position in ADMA Biologics by 305.5% during the 4th quarter. Man Group plc now owns 745,300 shares of the biotechnology company's stock valued at $12,782,000 after purchasing an additional 561,507 shares during the last quarter. 75.68% of the stock is owned by hedge funds and other institutional investors.

ADMA Biologics Stock Up 1.5%

ADMA Biologics stock traded up $0.27 during mid-day trading on Wednesday, reaching $18.53. The stock had a trading volume of 741,922 shares, compared to its average volume of 3,062,720. The company has a market capitalization of $4.42 billion, a price-to-earnings ratio of 21.78 and a beta of 0.43. The company has a debt-to-equity ratio of 0.22, a current ratio of 6.58 and a quick ratio of 3.36. ADMA Biologics Inc has a one year low of $10.21 and a one year high of $25.67. The company has a 50-day moving average price of $18.89 and a two-hundred day moving average price of $18.72.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 EPS for the quarter, missing analysts' consensus estimates of $0.16 by ($0.02). The business had revenue of $114.80 million during the quarter, compared to the consensus estimate of $116.40 million. ADMA Biologics had a return on equity of 47.16% and a net margin of 45.01%. The firm's revenue for the quarter was up 40.2% on a year-over-year basis. During the same period in the previous year, the business posted $0.08 EPS. On average, analysts expect that ADMA Biologics Inc will post 0.51 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently commented on the company. Wall Street Zen lowered ADMA Biologics from a "hold" rating to a "sell" rating in a research note on Friday, May 9th. Raymond James Financial upped their price target on ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a research note on Thursday, May 8th.

Insider Activity at ADMA Biologics

In other ADMA Biologics news, Director Jerrold B. Grossman sold 10,000 shares of ADMA Biologics stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $21.31, for a total value of $213,100.00. Following the completion of the sale, the director owned 478,194 shares of the company's stock, valued at approximately $10,190,314.14. The trade was a 2.05% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Steve Elms sold 194,749 shares of ADMA Biologics stock in a transaction on Monday, June 16th. The stock was sold at an average price of $20.24, for a total value of $3,941,719.76. Following the completion of the sale, the director directly owned 87,330 shares of the company's stock, valued at $1,767,559.20. The trade was a 69.04% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 464,621 shares of company stock worth $9,644,269 over the last quarter. Company insiders own 3.70% of the company's stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.